Clinical efficacy of anti-reflux therapy combined with tiotropium bromide in COPD patients with GERD
- Author:
- No author available
- Journal Title:
- World Chinese Journal of Digestology
- Issue:
- 9
- DOI:
- 10.11569/wcjd.v24.i9.1412
- Key Word:
- 慢性阻塞性肺疾病;胃食管反流病;抗反流治疗;噻托澳铵;Chronic obstructive pulmonary disease;Gastroesophageal reflux disease;Anti-reflux treatment;Tiotropium bromide
Abstract： 目的:探讨抗反流治疗联合噻托溴铵对伴有胃食管反流的慢性阻塞性肺病(chonic obstructive pulmonary disease,COPD)患者的临床疗效.方法:选取2014-01/2014-12在沧州和平医院就诊的48例COPD合并胃食管反流病(gastroesophageal reflux disease,GERD)患者作为研究对象,随机分为观察组和对照组,各24例,观察组给予埃索美拉唑、莫沙必利及噻托溴铵粉吸入剂治疗,对照组单纯给予噻托溴铵粉吸入剂治疗,比较两组患者治疗前后胃食管反流病评分量表(Gastroesophageal Reflux Disease-Q,GERD-Q)评分、慢性阻塞性肺病急性发作(AECOPD)次数以及临床疗效.结果:两组患者治疗1年后,GERD-Q评分:观察组明显下降(9.83±2.65vs15.23±3.75,P＜0.001),对照组下降不显著(13.32±3.02vs14.98±3.64,P＞0.05);两组患者AECOPD次数较治疗前均下降:观察组(1.08±0.30vs1.59±0.34),对照组(1.33±0.31vs1.60±0.41).而观察组较对照组下降更明显(1.08±0.30vs1.33±0.31,P＜0.01);临床疗效:两组COPD症状改善比较(91.6％vs87.50％,P＞0.05),观察组GERD症状显著优于对照组(95.83％vs66.67％,P＜0.01).结论:临床中对稳定期COPD合并GEGD患者给予抗反流治疗联合噻托溴铵是可行的,可有效改善GERD-Q评分、降低AECOPD次数、临床疗效显著.
- [1]李真,李延青.2013国际胃食管反流病诊断和管理指南解读[J].2013,(5).
- [2]中华医学会消化病学分会.2014年中国胃食管反流病专家共识意见[J].2014,(10).
- [3]侯俊珍,张莉.埃索美拉唑联合莫沙必利治疗胃食管反流病的疗效观察[J].2012,(5).
- [4]白澎,孙永昌.慢性阻塞性肺疾病合并症研究进展[J].2011,(9).
- [5]李小伟,薛见珍,刘栩.噻托溴铵联合信必可都保治疗稳定期COPD 的疗效观察[J].2015,(11).
- [6]陈玉昌.慢性阻塞性肺疾病合并胃食管反流病42例临床分析[J].2013,(25).
- [7]戴润芝,李谨,王丽欣.两种用药方案治疗食管反流性咽喉炎的疗效比较[J].2015,(6).
- [8]Carlos H, Martinez,Yuka, Okajima,Susan, Murray,etc.Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort.[J].2014,15.
- [9]王艳萍,姬林松,倪猛,等.新络纳联合耐信治疗胃食管反流病的临床效果比较[J].2014,(36).
- [10]Decramer M,Celli B,Senn S,etc.A 4-year trial of tiotropium in chronic obstructive pulmonary disease.[J].2008,359(15).
- [11]Michel, Suter.Comment on: Evaluation of gastroesophageal reflux before and after laparoscopic sleeve gastrectomy using symptom scoring, scintigraphy and endoscopy.[J].1900,10(4).